On this page of StockholderLetter.com we present the latest annual shareholder letter from Seer, Inc. — ticker symbol SEER. Reading current and past SEER letters to shareholders can bring important insights into the investment thesis.
202 ANNUAL REPORT
2XU *URZWK 6WUDWHJ\ Continue building evidence in the market to demonstrate the Proteograph s differentiated abilities to deliver unique, actionable biological insights. Enable and deliver large cohort studies to accelerate the market for deep, unbiased, proteomics at scale. Expand our user base by continuing to enhance access to the Proteograph. Innovate continuously to develop and commercialize additional transformative products to break down MS proteomic workflow barriers, access the proteome, and accelerate our understanding of biology.
FORM 10-K
 • shareholder letter icon 5/28/2025 Letter Continued (Full PDF)
 • stockholder letter icon 4/28/2023 SEER Stockholder Letter
 • stockholder letter icon 4/26/2024 SEER Stockholder Letter
 • stockholder letter icon More "Drugs & Pharmaceuticals" Category Stockholder Letters
 • Benford's Law Stocks icon SEER Benford's Law Stock Score = 67


SEER Shareholder/Stockholder Letter Transcript:

202  ANNUAL REPORT

2XU *URZWK 6WUDWHJ\ 
Continue building
evidence in the market to
demonstrate the
Proteograph   s
differentiated abilities to
deliver unique, actionable
biological insights.
Enable and deliver large
cohort studies to
accelerate the market for
deep, unbiased,
proteomics at scale.
Expand our user base by
continuing to enhance
access to the Proteograph.
Innovate continuously to
develop and
commercialize additional
transformative products
to break down MS
proteomic workflow
barriers, access the
proteome, and accelerate
our understanding of
biology.

FORM 10-K



shareholder letter icon 5/28/2025 Letter Continued (Full PDF)
 

SEER Stockholder/Shareholder Letter (Seer, Inc.) | www.StockholderLetter.com
Copyright © 2023 - 2025, All Rights Reserved

Nothing in StockholderLetter.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy.